Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease
Status:
RECRUITING
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity of LAD191 in healthy adults and in adults with an autoimmune disease.